CTOAM | Cancer Treatment Options & Management’s Post

Why might your oncologist resist ordering genetic testing for you? Find out in this short clip from our interview with one of the leading minds in Precision Medicine today, Dr. Razelle Kurzrock: https://buff.ly/3FIEyZW #GeneticTesting #PrecisionCancerMedicine

In the clip below, Mohammad Rafieetary , OD, FAAO, FORS, Dipl ABO, ABCMO talks about exciting new research involving genetic treatments for neovascular age-related macular degeneration (AMD) patients.

Desperate for answers and a solution to his health issues, Craig discovered clinical research and trials, leading him to undergo genetic testing with Invitae. This genetic test finally revealed his diagnosis of ADH1, a rare genetic condition related to hypoparathyroidism, which can cause chronically low levels of calcium in the blood and high levels of calcium in the urine. Let's bring awareness to the value of genetic testing, clinical trials, research, and accurate diagnoses for #WorldThyroidDay. 🧬🌍 #BehindTheMystery #ADH1 #ADH1Awareness #Hypoparathyroidism #RareDisease #RareDiseaseAwareness

Chromosomal Microarray Analysis (CMA) provides comprehensive genetic testing for chromosomal deletion and duplication conditions that might go undetected through traditional chromosome analysis. Widely recognized as a first-tier test in the pediatric setting for multiple congenital anomalies and/or intellectual disability, CMA can be ordered to evaluate individuals with developmental delays, including motor and social skills, language, and cognitive abilities. Our CMA can detect copy number changes ranging from small to large across the genome. Since launch, we have analyzed over 100,000 microarrays. When it comes to ordering CMA for your patients, you can trust our team of experts. For more details and to start a test order: https://bit.ly/3ZEvXRW Read our blog to learn more about CMA: https://bit.ly/3NfY5GA #ThinkBG #BGreat #Cytogenetics

June is #MensHealthMonth — a time to bring awareness to health issues often faced by men, such as infertility. Dr. Alexander Yatsenko, Magee-Womens investigator, utilizes molecular DNA, RNA, and novel genomic high-through put approaches to decipher genetic defects underlying male infertility. The goal? Improve clinical genetic diagnosis for infertile men via application of new genomic technologies and scientific findings into clinical practice. Learn more about how Dr. Yatsenko is tackling fertility challenges: https://bit.ly/4bPxIk0

📢📰 This manuscript, published in Modern Pathology, contains a review of the WHO-HEM5 revisions to the classification of myeloid neoplasms, which includes major updates & revisions with an increased emphasis on genetic & molecular drivers of disease. READ➡️https://lnkd.in/e5CH-hWT

Contractile performance in cardiomyocytes has long served as a key measure of cardiac response to compound treatment as well as genetic modification and pathophysiological conditions. IonOptix offers several contractility algorithms suited to different cardiomyocyte preparations. In this comparison video, we identify the appropriate algorithm to use for primary or cultured cells, as well as specific use cases for each. We also illustrate usage and best practices while describing some of each algorithm’s underlying technology. Interested in more information?  Contact us or visit our website!  >>  https://lnkd.in/eHuN9Etn #CardiacResearch #IonOptix #CalciumandContractility #CytoMotionLite #MultiCellHTS

Maximize Your Research with the Right Contractility Algorithm! Contractile performance in cardiomyocytes has long served as a key measure of cardiac response to compound treatment as well as genetic modification and pathophysiological conditions. We identify the appropriate algorithm to use for primary or cultured cells, as well as specific use cases for each in this comparison video. We also illustrate usage and best practices while describing some of each algorithm’s underlying technology. Don’t miss out on this essential resource to advance your cardiac research! 👉 Watch the video now - https://lnkd.in/eHuN9Etn

Study on 37 patients with congenital myasthenic syndromes highlights the need for genetic diagnosis for effective treatment. - Belgium prevalence: 3.19 per 1M. - Treatment depends on genetic defect. - Normal electrophysiology doesn't rule out CMS. https://lnkd.in/dR23NB8i

In The FASEB Journal: New research highlights the vital contribution of Xbp1 to odontoblastic differentiation by regulating mitochondrial balance, providing insights into potential therapies for mitochondrial disorders stemming from genetic anomalies. Read more in The FASEB Journal: https://hubs.ly/Q02sKbVD0